Clinical Trial Update: Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC [Phase 2]

View source ↗

Summary

A Phase 2 study of PULSAR-ICI with or without IMSA101 in patients with oligometastatic non-small cell lung cancer and renal cell carcinoma was terminated, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• IMSA101
• PULSAR-ICI

Snippet

Sponsor: ImmuneSensor Therapeutics Inc. | Conditions: Oligometastatic Disease | Phase 2 | Status: TERMINATED | Results posted: 2025-10-20